Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry

BACKGROUND: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). AIM: To evaluate effectiveness, safety and use of tofacitinib in daily practice. METHODS: UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Cort...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Aliment Pharmacol Ther
Päätekijät: Biemans, Vince B. C., Sleutjes, Jasmijn A. M., de Vries, Annemarie C., Bodelier, Alexander G. L., Dijkstra, Gerard, Oldenburg, Bas, Löwenberg, Mark, van Bodegraven, Adriaan A., van der Meulen‐de Jong, Andrea E., de Boer, Nanne K. H., Srivastava, Nidhi, West, Rachel L., Römkens, Tessa E. H., Horjus Talabur Horje, Carmen S., Jansen, Jeroen M., van der Woude, C. Janneke, Hoekstra, Jildou, Weersma, Rinse K., van Schaik, Fiona D. M., Hoentjen, Frank, Pierik, Marieke J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Tofacitinib for Ulcerative Colitis
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7187329/
https://ncbi.nlm.nih.gov/pubmed/32237087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15689
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia